Joel Greenblatt fit · Magic Formula — ROIC alto + EV/EBIT barato
Is Acadia Pharmaceuticals Inc. (ACAD) a Joel Greenblatt Stock?
Partial match — either cheap or high-quality, but not both.
62/100
CSinais mistos
2/5 critérios atendidos
Os critérios de Joel Greenblatt, aplicados a ACAD
EBIT/EV yield ≥ 10%
chave3.6%
ROIC ≥ 25%
chave25.2%
EV/EBIT ≤ 12
27.7x
Gross margin ≥ 30%
91.9%
Como ACAD pontua em outras estratégias
Dados financeiros ao vivo
Cap. de mercado
$4.65B
P/L (TTM)
19.0x
ROIC (TTM)
25.22%
Margem bruta
91.92%
Perguntas frequentes
What is ACAD's Joel Greenblatt fit score?
ACAD scores 62/100 on our Joel Greenblatt fit engine — grade C. Partial match — either cheap or high-quality, but not both.
Does Joel Greenblatt actually own ACAD?
Our score is computed from financial fundamentals against Joel Greenblatt's published criteria. We don't claim that Joel Greenblatt personally owns or recommends ACAD.
How often is this score updated?
ACAD's Joel Greenblatt fit score is recomputed daily from the latest TTM financials.
Ferramenta educacional, não é consultoria de investimento. As pontuações são calculadas a partir de dados financeiros públicos contra os critérios publicados de cada estratégia de investimento. Não afirmamos que Joel Greenblatt possua ou recomende ACAD pessoalmente.